Myriad Genetics Inc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report3 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Myriad Genetics Inc
6.36
Expected move
Inputsspot 6.35exp Nov 20ATM strike 6ATM straddle 1.43IV 118%
−46.74%
vs ±20.0% implied · ×2.34
shaded = implied · ▲▼ = realized
Linked news
NewsMyriad Genetics has 6 disclosed suppliers and 3 disclosed customers in SEC filings.
SentenceFor example, we license the rights from Eurobio Scientific to sell EndoPredict as a laboratory developed test outside of the European Union.
MYGN 10-Kaccession 0000899923-26-000018
SentenceFor example, on February 1, 2024, we acquired the Precise Tumor Test and a CLIA certified laboratory from Intermountain Healthcare and on November 1, 2022, we acquired Gateway Genomics, LLC (Gateway), a personal genomics company and developer of consumer genetic tests that gives families genetic insight into their future children.
MYGN 10-Kaccession 0000899923-26-000018
SentenceFor example, on February 1, 2024, we acquired the Precise Tumor Test and a CLIA certified laboratory from Intermountain Healthcare and on November 1, 2022, we acquired Gateway Genomics, LLC (Gateway), a personal genomics company and developer of consumer genetic tests that gives families genetic insight into their future children.
MYGN 10-Kaccession 0000899923-26-000018
SentenceAt the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, we and our collaborators from the National Cancer Center Hospital East in Japan presented results from the MONSTAR-SCREEN 3 study, which reported 100 percent baseline sensitivity and highly sensitive detection of residual disease post-surgery.
MYGN 10-Kaccession 0000899923-26-000018
SentenceIn early 2025, we entered into a strategic collaboration with PATHOMIQ, Inc. pursuant to which we obtained exclusive U.S. licen sing rights to PATHOMIQ's AI-enabled diagnostic platform, PATHOMIQ_PRAD, to enhance our oncology portfolio and offer AI-driven prognostic and predictive solutions for prostate cancer care.
MYGN 10-Kaccession 0000899923-26-000018
SentenceIn September 2025, we entered into a strategic collaboration with SOPHiA GENETICS S.A. to develop a global liquid biopsy companion diagnostic solution.
MYGN 10-Kaccession 0000899923-26-000018
SentenceFor example, in 2024, UnitedHealthcare updated its medical policy for pharmacogenetic testing to no longer provide coverage for certain multi-gene panel pharmacogenetic tests, including our GeneSight test, under its commercial, individual exchange and certain managed Medicaid plans.
SentenceAs part of the transaction, we licensed the rights from Eurobio to continue to sell EndoPredict as a laboratory developed test outside of the European Union and we licensed to Eurobio the rights to sell Prolaris in vitro diagnostic kits outside the U.S.
MYGN 10-Kaccession 0000899923-26-000018